DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2019 年 04 月 08 日 1:00 下午 - 2019 年 04 月 10 日 4:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Biostatistics Industry and Regulator Forum

Session 9:Unhealthy Safety Assessment: Moving Towards Better Characterization of Patient Harms

Session Chair(s)

Mat  Soukup, PhD

Mat Soukup, PhD

Deputy Director, Division of Biometrics VII, OB, OTS CDER

FDA, United States

Brenda  Crowe, PhD

Brenda Crowe, PhD

Associate Vice President, Statistics

Eli Lilly and Company, United States

Frank W. Rockhold, PhD, MSc

Frank W. Rockhold, PhD, MSc

Professor of Biostatistics

Duke Clinical Research Institute, Duke University Medical Center, United States

The amount of information collected in clinical trials is weighted more to safety than benefit; however, a disproportionate number of statisticians are involved in assessing the benefits of a pharmaceutical product relative to the number of statisticians assessing the risks. This is also reflected in the literature around new medicines. It is important for there to be a statistical presence in the evaluation of safety as the questions can be complex and require novel statistical solutions; even in simple cases, such as calculating rates across trials, a lack of statistical presence has resulted in inadequate and improper approaches being utilized.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand common clinical issues that arise when characterizing the safety (and benefit-risk) of a pharmaceutical product
  • Identify the rationale and motivation for an increased statistical presence in assessing risks
  • Apply good statistical practice for safety related topics

Speaker(s)

Christopher B. Granger, MD

Unhealthy Safety Assessment: Moving Towards Better Characterization of Patient Harms

Christopher B. Granger, MD

Duke University Medical Center, United States

Professor of Medicine; Director, Cardiac Intensive Care Unit

Steffen  Unkel

Estimands and the Analysis of Adverse Events in the Presence of Varying Follow-Up Times Within the Benefit Assessment of Therapies

Steffen Unkel

University Medical Center Göttingen, Germany

Department of Medical Statistics

Peter  Stein, MD

Improved Characterization of Patient Harms: A Regulatory Perspective

Peter Stein, MD

Peter Stein Consulting, LLC, United States

Consultant

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。